A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Exclusion Criteria

• •Has other histological subtypes of NSCLC (e.g., small cell or neuroendocrine)
• •Has active or untreated CNS metastases or carcinomatous meningitis
• •Prior treatment with KRAS G12C inhibitors, FAK inhibitors, or immune checkpoint inhibitors
• •Has another known driver mutation with approved targeted therapy (e.g., EGFR, ALK, ROS1)
• •Has uncontrolled cardiovascular disease, active severe infection, interstitial lung disease, or autoimmune disease requiring systemic therapy
• •Has history of another malignancy within 5 years, except those curatively treated and considered low risk (e.g., basal cell carcinoma, cervical carcinoma in situ)
• •Has gastrointestinal conditions that may interfere with absorption of oral drugs (if applicable)
• •Has known active hepatitis B, hepatitis C, or HIV infection
• •Has received a live vaccine within 30 days before first dose of study drug
• •Pregnant or breastfeeding women
• •Has psychiatric or substance abuse disorders that would interfere with study compliance
• •Is participating in another interventional clinical study
• •Any condition that, in the opinion of the Investigator, would interfere with participation or study results